JP5211677B2 - Oral solution - Google Patents
Oral solution Download PDFInfo
- Publication number
- JP5211677B2 JP5211677B2 JP2007327657A JP2007327657A JP5211677B2 JP 5211677 B2 JP5211677 B2 JP 5211677B2 JP 2007327657 A JP2007327657 A JP 2007327657A JP 2007327657 A JP2007327657 A JP 2007327657A JP 5211677 B2 JP5211677 B2 JP 5211677B2
- Authority
- JP
- Japan
- Prior art keywords
- diphenhydramine
- purified water
- erythritol
- adjusted
- sucralose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940100688 oral solution Drugs 0.000 title claims description 11
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 31
- 239000004386 Erythritol Substances 0.000 claims description 30
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 30
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 30
- 235000019414 erythritol Nutrition 0.000 claims description 30
- 229940009714 erythritol Drugs 0.000 claims description 30
- 229960000520 diphenhydramine Drugs 0.000 claims description 29
- 239000004376 Sucralose Substances 0.000 claims description 26
- 235000019408 sucralose Nutrition 0.000 claims description 26
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 18
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 14
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 11
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 11
- 229960004998 acesulfame potassium Drugs 0.000 claims description 11
- 239000000619 acesulfame-K Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000005711 Benzoic acid Substances 0.000 claims description 7
- 235000010233 benzoic acid Nutrition 0.000 claims description 7
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 60
- 239000008213 purified water Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 28
- 230000000052 comparative effect Effects 0.000 description 28
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 28
- 238000003756 stirring Methods 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 22
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 20
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 20
- 239000003205 fragrance Substances 0.000 description 20
- 239000001630 malic acid Substances 0.000 description 20
- 235000011090 malic acid Nutrition 0.000 description 20
- 238000004090 dissolution Methods 0.000 description 19
- 239000001509 sodium citrate Substances 0.000 description 19
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 19
- 239000000796 flavoring agent Substances 0.000 description 18
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 17
- 235000013736 caramel Nutrition 0.000 description 17
- 235000019634 flavors Nutrition 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 238000011156 evaluation Methods 0.000 description 15
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 15
- 239000004299 sodium benzoate Substances 0.000 description 15
- 235000010234 sodium benzoate Nutrition 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 235000019640 taste Nutrition 0.000 description 13
- 235000019658 bitter taste Nutrition 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 241000233866 Fungi Species 0.000 description 8
- 230000002421 anti-septic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000002925 dental caries Diseases 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229940067596 butylparaben Drugs 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000820 nonprescription drug Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- NFLLKCVHYJRNRH-UHFFFAOYSA-N 8-chloro-1,3-dimethyl-7H-purine-2,6-dione 2-(diphenylmethyl)oxy-N,N-dimethylethanamine Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Cl)=N2.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 NFLLKCVHYJRNRH-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000598 endocrine disruptor Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000005554 hypnotics and sedatives Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- -1 pH adjusters Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、種々の菌・カビに対する防腐力に優れ、ジフェンヒドラミンの安定性が高く、味・風味も良好な、低カロリーかつ、低う蝕性のジフェンヒドラミン配合睡眠改善内服液剤に関する。具体的には、ジフェンヒドラミン及び/またはその塩類、安息香酸及び/またはその塩類、及びエリスリトールを含有し、pH3.8〜4.2とした睡眠改善内服液剤に関する。 The present invention relates to a low-calorie, low-cariogenic diphenhydramine-containing sleep-improving sleep fluid that has excellent antiseptic power against various fungi and fungi, has high stability of diphenhydramine, and has good taste and flavor. Specifically, the present invention relates to a sleep improving oral solution containing diphenhydramine and / or a salt thereof, benzoic acid and / or a salt thereof, and erythritol and having a pH of 3.8 to 4.2.
ジフェンヒドラミンは、古くからヒスタミンH1受容体拮抗薬(抗ヒスタミン薬)として内服薬・外用剤を問わず、広く使用されてきた安全性の高い薬剤である。また、覚醒の維持に関与するヒスタミンの働きを抑制することから、催眠鎮静作用を表すことが知られている。ジフェンヒドラミンは、抗ヒスタミン薬の中でもとくに催眠鎮静作用が強く、欧米では睡眠導入を目的としたOTC薬としても利用されている。
近年、日本でも、医師の処方箋が必要とされない一般用医薬品において、睡眠改善薬や乗り物酔い(鎮暈薬)及び肌のかゆみ止めなど、多様な薬効及び多種の剤型として幅広く使用されている(非特許文献1〜3 参照)。
Diphenhydramine is a highly safe drug that has been widely used as a histamine H1 receptor antagonist (antihistamine) regardless of whether it is used internally or externally. Moreover, since it suppresses the action of histamine involved in maintaining arousal, it is known to exhibit hypnotic sedation. Diphenhydramine has a particularly strong hypnotic sedative effect among antihistamines and is also used as an OTC drug for the purpose of introducing sleep in Europe and the United States.
In recent years, in Japan, over-the-counter drugs that do not require a doctor's prescription are widely used as various medicinal properties and various dosage forms, such as sleep-improving drugs, motion sickness (antipruritic drugs), and skin itching prevention Patent Documents 1 to 3).
睡眠改善剤は、その用途から就寝前に服用するのが通常であるが、服薬の簡便化や、即効性を期待するために、内服用液剤の開発が望まれていた。
しかし、ジフェンヒドラミンや塩酸ジフェンヒドラミンに代表されるジフェンヒドラミンの塩類は特有の苦みと舌を麻ひさせる特異的な味を有する薬物であるため、その苦味と味をマスキングしなければとても服用に適するものではない。
錠剤の場合、糖衣錠、フィルムコート錠、チュアブル錠など構造上の工夫を加えることで、これらの持つ苦味と、舌を麻ひする特異的な味をマスキングしている(特許文献1 参照)。
ところが、この薬物を内服用液剤にする場合には、他の配合成分とのバランスも考慮する必要があり、マスキングすることが非常に難しい。
The sleep-improving agent is usually taken before going to bed because of its use, but in order to simplify the medication and expect immediate effects, the development of a liquid for internal use has been desired.
However, diphenhydramine salts represented by diphenhydramine and diphenhydramine hydrochloride are drugs that have specific bitterness and a specific taste that paralyzes the tongue, and are not very suitable for taking unless the bitterness and taste are masked.
In the case of tablets, the bitterness of these tablets and the specific taste that paralyzes the tongue are masked by adding structural ingenuity such as sugar-coated tablets, film-coated tablets, and chewable tablets (see Patent Document 1).
However, when this drug is used as a liquid for internal use, it is necessary to consider the balance with other ingredients, and masking is very difficult.
一般に、このような苦味を有する薬物に対しては、服用しやすくするため、大量の糖類によるマスキングを行うのが通常である。例えば、カプセル剤や錠剤、散剤などの剤形では小児に服用させることが難しいため、服用コンプライアンス向上のため、小児用シロップ剤が汎用されているが、飲みやすくするため、大量の糖類が添加されている(非特許文献4 参照 )。
しかし、糖類などの甘味剤によるマスキング方法を用いると、高カロリーの飲料を就寝前に服用することとなる。近年は過食、運動不足によって内臓脂肪が蓄積し、高血圧症、高脂血症、糖尿病など複数の生活習慣病を合併するメタボリックシンドロームの予防が重視されている。従って、睡眠改善剤としての効果を有していても、肥満やメタボリックシンドロームが危惧されることは望ましくない。さらに、就寝前に服用しそのまま就寝すると、う蝕の問題も生じるため、虫歯の予防のために、服用後に再び歯磨きをする必要が生じるなど、服用コンプライアンスが著しく低下することとなる。
In general, a drug having such a bitter taste is usually masked with a large amount of sugars in order to make it easier to take. For example, it is difficult for children to take capsules, tablets, powders and other dosage forms, so pediatric syrups are widely used to improve compliance, but large amounts of sugar are added to make them easier to drink. (See Non-Patent Document 4).
However, if a masking method using a sweetener such as sugar is used, a high-calorie beverage is taken before going to bed. In recent years, emphasis has been placed on prevention of metabolic syndrome in which visceral fat accumulates due to overeating and lack of exercise, and is associated with multiple lifestyle-related diseases such as hypertension, hyperlipidemia, and diabetes. Therefore, even if it has an effect as a sleep improving agent, it is not desirable to be anxious about obesity and metabolic syndrome. Furthermore, if you take it before going to bed and go to bed as it is, you will also have a problem of caries, and you will need to brush your teeth again after taking to prevent tooth decay.
さらに、塩酸ジフェンヒドラミンの内服液剤は、特に低いpHの酸性域で分解が進むことが知られており、ある程度pHを高くする必要が生じる一方、液剤では、他の薬剤型に比べ細菌が繁殖する可能性が高く、防腐力を付与する必要がある。そのため、高いpH域でも安定な防腐力を示す、パラベン類が汎用されている(特許文献2 参照 )。
しかし、パラベン類は独特のえぐ味を持つことから、液剤の風味が悪くなるという欠点がある。特に、ジフェンヒドラミンの液剤においては、ジフェンヒドラミン自体が有する苦味と相俟って、さらに著しく味が低下することとなる。
しかも、内服液剤に汎用されているパラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピルは、環境ホルモン物質(内分泌かく乱化学物質)の疑いがあるとされている。環境ホルモンは人の体に入り込むと、もともとある体内のホルモンと結びついて、正常なホルモンバランスを崩す可能性があることが示唆されている。また、ラットによる実験では、このパラベンに精子を減らす作用があることが報告されている(非特許文献5)。
In addition, it is known that the internal solution of diphenhydramine hydrochloride progresses particularly in the acidic region of low pH, and it is necessary to raise the pH to some extent, but in the liquid, bacteria can propagate compared to other drug types. It is necessary to provide antiseptic power. Therefore, parabens that exhibit stable antiseptic power even in a high pH range are widely used (see Patent Document 2).
However, since parabens have a peculiar taste, there is a drawback that the flavor of the liquid agent becomes worse. In particular, in the diphenhydramine solution, the taste is further significantly reduced in combination with the bitter taste of diphenhydramine itself.
In addition, ethyl paraoxybenzoate, butyl paraoxybenzoate, and propyl paraoxybenzoate, which are widely used in oral liquid preparations, are suspected of being environmental hormone substances (endocrine disrupting chemical substances). It has been suggested that environmental hormones, when they enter the human body, can be linked to the hormones in the body and disrupt the normal hormonal balance. In experiments with rats, it has been reported that this paraben has an effect of reducing sperm (Non-patent Document 5).
このため、薬剤としてより安全に服用するためには、ジフェンヒドラミンの安定性を確保しつつ、パラベン類を使用せずに十分な防腐力を有しており、その上でジフェンヒドラミンの苦味及び舌へのしびれ感がマスキングされた、就寝直前にも、容易に服用可能な睡眠改善剤が求められていた。
本発明は、種々の菌・カビに対する防腐力に優れ、ジフェンヒドラミンの安定性が高く、味・風味も良好なジフェンヒドラミン配合睡眠改善内服液剤を提供することを目的とする。具体的には、ジフェンヒドラミン及び/またはその塩類、安息香酸及び/またはその塩類、及びエリスリトールを含有し、pH3.8〜4.2とした睡眠改善内服液剤に関する。
さらに、就寝前の服用を考慮し、低カロリーかつ、う蝕性の観点からも服用コンプライアンスの改善された睡眠改善内服液剤を提供することも目的とする。
An object of the present invention is to provide a diphenhydramine-containing sleep-improving oral liquid composition that is excellent in antiseptic power against various fungi and molds, has high stability of diphenhydramine, and has good taste and flavor. Specifically, the present invention relates to a sleep improving oral solution containing diphenhydramine and / or a salt thereof, benzoic acid and / or a salt thereof, and erythritol and having a pH of 3.8 to 4.2.
It is another object of the present invention to provide a sleep-improving oral solution with improved compliance from the viewpoint of low calorie and caries, considering taking before bedtime.
本発明者らは、前述の課題を解決すべく鋭意研究を重ねた結果、ジフェンヒドラミン及び/またはその塩類、安息香酸及び/またはその塩類及びエリスリトールを含有する、pH3.8〜4.2の睡眠改善内服液剤とすることで、種々の菌・カビに対する防腐力に優れ、ジフェンヒドラミンの安定性が高く、味、風味も良好な内服液剤が得られることを見出した。
また、エリスリトールの含有量を、5〜20W/V%とすることにより、低カロリーかつ、う蝕性の問題を生ずることなく、ジフェンヒドラミン及び/またはその塩の苦味をマスキングした内服液剤が得られることを見出し、本発明を完成するに至った。
As a result of intensive studies to solve the above-mentioned problems, the present inventors have improved sleep at pH 3.8 to 4.2 containing diphenhydramine and / or its salts, benzoic acid and / or its salts and erythritol. It has been found that by using an internal solution, an internal solution having excellent antiseptic power against various fungi and fungi, high stability of diphenhydramine, and good taste and flavor can be obtained.
Moreover, by setting the content of erythritol to 5 to 20 W / V%, an internal liquid preparation masking the bitter taste of diphenhydramine and / or a salt thereof can be obtained without causing low calorie and caries problems. As a result, the present invention has been completed.
すなわち、本発明は、下記[1]〜[5]に掲げる内服液剤である。
[1]ジフェンヒドラミン及び/またはその塩類、安息香酸及び/またはその塩類、及びエリスリトールを含有する、pH3.8〜4.2の睡眠改善内服液剤
[2]エリスリトールの含有量が、5〜20W/V%である[1]に記載の睡眠改善内服液剤。
[3]パラベン類を含まないことを特徴とする[1]または[2]に記載の睡眠改善内服液剤。
[4]さらに、スクラロース及び/またはアセスルファムカリウムから選ばれる1種以上を含有する[1]、[2]または[3]に記載の睡眠改善内服液剤。
[5]100mLあたりのエネルギーが、20kcal以下である[1]、[2]、[3]または、[4]に記載の睡眠改善内服液剤。
That is, this invention is an internal use liquid agent hung up to the following [1]-[5].
[1] An agent for improving sleep of pH 3.8 to 4.2 containing diphenhydramine and / or a salt thereof, benzoic acid and / or a salt thereof, and erythritol
[2] The sleep improving oral solution according to [1], wherein the content of erythritol is 5 to 20 W / V%.
[3] The liquid for improving sleep according to [1] or [2], which does not contain parabens.
[4] The sleep improving liquid preparation according to [1], [2] or [3], further comprising at least one selected from sucralose and / or acesulfame potassium.
[5] The sleep improving oral solution according to [1], [2], [3] or [4], wherein energy per 100 mL is 20 kcal or less.
本発明における内服液剤とは、特に制限はないが、例えば、公知の使用形態として汎用される医薬品、新指定医薬部外品などに分類されるビタミン含有保健薬と同じ方法により調製したドリンク剤を指す。 The internal liquid preparation in the present invention is not particularly limited, for example, a drink prepared by the same method as a vitamin-containing health medicine classified as a commonly used pharmaceutical product, a newly designated quasi-drug, etc. Point to.
本発明で用いられるジフェンヒドラミン及び/またはその塩類は、通常の医薬品に使用されるものであればよく、例えば第15改正 日本薬局方収載品の塩酸ジフェンヒドラミンを使用することができる。ジフェンヒドラミン及び/またはその塩類の濃度は、0.01〜1.0W/V%の範囲であることが好ましく、特に好ましくは0.08〜0.5W/V%であることが望ましい。ジフェンヒドラミン及び/またはその塩類の濃度が0.01W/V%未満では、睡眠改善効果が十分に発揮できない一方で、ジフェンヒドラミン及び/またはその塩類の濃度が1.0W/V%より多いと内服液剤の味が損なわれるため好ましくない。 The diphenhydramine and / or salts thereof used in the present invention may be those used in ordinary pharmaceuticals. For example, diphenhydramine hydrochloride listed in the 15th revised Japanese pharmacopoeia can be used. The concentration of diphenhydramine and / or a salt thereof is preferably in the range of 0.01 to 1.0 W / V%, particularly preferably 0.08 to 0.5 W / V%. When the concentration of diphenhydramine and / or its salt is less than 0.01 W / V%, the sleep-improving effect cannot be sufficiently exerted. On the other hand, when the concentration of diphenhydramine and / or its salt is more than 1.0 W / V%, This is not preferable because the taste is impaired.
本発明で用いられる安息香酸及び/またはその塩は、通常の医薬品に使用されるものであればよく、例えば第15改正 日本薬局法収載の安息香酸ナトリウムを使用することができる。 The benzoic acid and / or salt thereof used in the present invention may be any benzoic acid and / or salt thereof as long as it is used in ordinary pharmaceuticals. For example, sodium benzoate listed in the 15th revised Japanese pharmacy law can be used.
本発明で用いられるエリスリトールは、通常の医薬品に使用されるものであればよく、例えば、医薬品添加物規格収載品を使用することができる。エリスリトールの濃度は、5〜20W/V%の範囲であることが好ましく、特に好ましくは7〜15W/V%の範囲であることが望ましい。
エリスリトールの濃度が5W/V%未満では、ジフェンヒドラミンの苦味と舌を麻痺する特異的な味を抑える効果が低下する。さらに、当該発明の内服液剤の防腐効力も低下する。また、エリスリトールの濃度が20W/V%より多いと溶解度の面で問題が生じ、製造法が煩雑となり、好ましくない。
The erythritol used by this invention should just be used for a normal pharmaceutical, for example, a pharmaceutical additive specification listed product can be used. The concentration of erythritol is preferably in the range of 5 to 20 W / V%, particularly preferably in the range of 7 to 15 W / V%.
If the concentration of erythritol is less than 5 W / V%, the effect of suppressing the bitter taste of diphenhydramine and the specific taste that numb the tongue is reduced. Furthermore, the antiseptic effect of the internal use liquid preparation of the said invention also falls. On the other hand, if the concentration of erythritol is higher than 20 W / V%, a problem arises in terms of solubility, and the production method becomes complicated, which is not preferable.
本発明では必要に応じて高甘味剤を添加することが可能である。例えば、スクラロース、アセスルファムカリウム、ソーマチン、羅漢果、ステビア、サッカリンなどが使用できる。これらの中でも、特に風味が向上するのはスクラロースであり、さらに、アセスルファムカリウムまたは、この2種を併用したものも風味が向上する。 In the present invention, a high sweetener can be added as necessary. For example, sucralose, acesulfame potassium, thaumatin, rahan fruit, stevia, saccharin and the like can be used. Among these, sucralose has a particularly improved flavor, and acesulfame potassium or a combination of these two types also improves the flavor.
スクラロースを使用する場合、通常の医薬品に使用されるものであればよく、例えば医薬品添加物規格収載品を使用することができる。スクラロースの濃度は、0.03〜0.3W/V%の範囲であることが好ましく、特に好ましくは0.05〜0.2W/V%であることが望ましい。スクラロースの濃度が0.03W/V%では、ジフェンヒドラミンの苦味と、舌を麻ひする特異的な味を抑える効果が乏しく、また、スクラロースの濃度が0.3W/V%より多いと甘味が強すぎて好ましくない。 When sucralose is used, it may be used as long as it is used for ordinary pharmaceuticals, and for example, a pharmaceutical additive standard listed product can be used. The concentration of sucralose is preferably in the range of 0.03 to 0.3 W / V%, particularly preferably 0.05 to 0.2 W / V%. When the sucralose concentration is 0.03 W / V%, the effect of suppressing the bitter taste of diphenhydramine and the specific taste that paralyzes the tongue is poor, and when the sucralose concentration is higher than 0.3 W / V%, the sweetness is too strong. It is not preferable.
アセスルファムカリウムを使用する場合は、通常の医薬品に使用されるものであればよい。アセスルファムカリウムの濃度は、0.03〜0.6W/V%の範囲であることが望ましく、特に好ましくは、0.06〜0.4W/V%であることが好ましい。アセスルファムカリウムの濃度が、0.03W/V%より少ないと、ジフェンヒドラミンの苦味と、舌を麻ひする特異的な味を抑えることが難しく、またアセスルファムカリウムの濃度が、0.6W/V%より多いと、甘味が強すぎて、内服液剤の香味を損なう。 When acesulfame potassium is used, it may be used as long as it is used for ordinary pharmaceuticals. The concentration of acesulfame potassium is desirably in the range of 0.03 to 0.6 W / V%, particularly preferably 0.06 to 0.4 W / V%. If the concentration of acesulfame potassium is less than 0.03 W / V%, it is difficult to suppress the bitter taste of diphenhydramine and the specific taste that paralyzes the tongue, and the concentration of acesulfame potassium is more than 0.6 W / V%. And the sweetness is too strong, and the flavor of the oral solution is impaired.
本発明におけるパラベン類とは、パラオキシ安息香酸アルキルエステルであり、アルキルエステルの炭素数としては、2〜4、例えば第15改正日本薬局方収載のパラオキシ安息香酸エチル、パラオキシ安息香酸プロピルまたはパラオキシ安息香酸ブチルなどがあげられる。 Parabens in the present invention are alkyl esters of paraoxybenzoic acid, and the alkyl ester has 2 to 4, for example, ethyl paraoxybenzoate, propyl paraoxybenzoate or paraoxybenzoic acid listed in the 15th revised Japanese Pharmacopoeia. Examples include butyl.
本発明における低カロリーとは、健康増進法第31条に基づいた栄養表示基準で定める栄養成分表示の「エネルギー」のことであり、栄養成分がすくないことを強調する場合の基準と同様である。すなわち、100mLあたりのエネルギーが20kcal以下であることをいう。本発明においては、さらに「エネルギー」が、10kcal以下であることが好ましく、さらに7kcal未満がより好ましい。 The low calorie in the present invention means “energy” of nutritional component labeling defined by the nutrition labeling standard based on Article 31 of the Health Promotion Act, and is the same as the standard in the case of emphasizing that the nutritional component is scarce. That is, the energy per 100 mL is 20 kcal or less. In the present invention, “energy” is preferably 10 kcal or less, more preferably less than 7 kcal.
本発明の内服液剤には、甘味剤のほか、必要に応じて、味、風味をより良くするために、必要に応じて、以下に示すような添加剤を加えることができる。すなわち、クエン酸、酒石酸、リンゴ酸、乳酸などの酸味剤、矯味剤、安定化剤、溶解補助剤、pH調整剤、粘調剤、造粘剤そして、香料等が挙げられる。これらは、1種単独で使用してもよく、2種以上併用してもよい。これらの成分は、従来の経口液剤に使用されている量で適宜配合されることが望ましい。 In addition to sweeteners, additives as shown below can be added to the internal liquid preparation of the present invention as necessary in order to improve the taste and flavor as needed. That is, examples include sour agents such as citric acid, tartaric acid, malic acid, and lactic acid, flavoring agents, stabilizers, solubilizers, pH adjusters, thickeners, thickeners, and fragrances. These may be used alone or in combination of two or more. These components are desirably blended appropriately in amounts used in conventional oral solutions.
このようにして得られた本発明のジフェンヒドラミン及び/その塩を含有する睡眠改善内服液剤は、防腐力と安定性の双方を満たし、液剤であるため服用コンプライアンスが高く、さらに低カロリーかつ、低う触性であるため、就寝前の服用に非常に適している。 The thus obtained sleep-improving oral solution containing diphenhydramine and / or a salt thereof of the present invention satisfies both antiseptic power and stability, and is a liquid agent, so it has high compliance, and is low in calories and low. Because it is tactile, it is very suitable for taking before bedtime.
(内服液剤の調製方法)
本発明の内服液剤の調製方法としては、特に制限されず、通常の内服液剤を調製するのに必要な各種成分を適宜選択、配合して、常法により調製することができる。
通常、各成分と精製水の一部を混合、溶解、必要であれば加熱し溶解し、製剤の至適pHを得るため、酸又はアルカリを用いて、調整した後、精製水などで液量を調整後、不溶物除去のため、必要に応じてろ過するのも良い。
(Method for preparing oral solution)
The method for preparing the internal liquid preparation of the present invention is not particularly limited, and various components necessary for preparing a normal internal liquid preparation can be appropriately selected and blended and prepared by a conventional method.
Usually, each component and a part of purified water are mixed and dissolved. If necessary, dissolve by heating to obtain the optimum pH of the preparation. After the adjustment, it may be filtered as necessary to remove insoluble matters.
次に、実施例及び、比較例を挙げて、本発明を具体的に説明するが、本発明は、これら実施例に限定されるものではない。 Next, although an Example and a comparative example are given and this invention is demonstrated concretely, this invention is not limited to these Examples.
[実施例1]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを3.8に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 1]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, caramel 0.75 g and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 3.8, and the total volume is adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例2]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 2]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, caramel 0.75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例3]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.2に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 3]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, 0.75 g of caramel and a fragrance are sequentially added with stirring. After confirming dissolution, the pH is adjusted to 4.2, and the total volume is adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例4]
加温した精製水400mLに、エリスリトール45gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 4]
In 400 mL of warm purified water, 45 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, caramel 0.75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例5]
加温した精製水400mLに、エリスリトール180gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 5]
In 400 mL of heated purified water, 180 g of erythritol was stirred and dissolved, and 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and 0.1% of sucralose. 6 g, caramel 0.75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例6]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、アセスルファムカリウム1.2g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 6]
In 400 mL of heated purified water, 90 g of erythritol was dissolved with stirring. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, acesulfame potassium 1 .2 g, caramel 0.75 g and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例7]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム4.5g、クエン酸2.85g、リンゴ酸3.6g、塩酸ジフェンヒドラミン0.45g、スクラロース0.27g、アセスルファムカリウム0.27g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い、本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 7]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved, and 0.63 g of sodium benzoate, 4.5 g of sodium citrate, 2.85 g of citric acid, 3.6 g of malic acid, 0.45 g of diphenhydramine hydrochloride, and 0.4% of sucralose. 27 g, acesulfame potassium 0.27 g, caramel 0.75 g and a fragrance were sequentially added with stirring, and after confirming dissolution, the pH was adjusted to 4.0, and the total volume was adjusted to 900 mL with purified water. This apparatus was filtered using a device with a filter paper as a filter layer, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[実施例8]
加温した精製水400mLに、エリスリトール135gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム11.4g、クエン酸5.7g、リンゴ酸8.4g、塩酸ジフェンヒドラミン6g、スクラロース1.5g、アセスルファムカリウム2.4g、カラメル0.9g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Example 8]
In 400 mL of heated purified water, 135 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 11.4 g of sodium citrate, 5.7 g of citric acid, 8.4 g of malic acid, 6 g of diphenhydramine hydrochloride, 1.5 g of sucralose, 2.4 g of acesulfame potassium, 0.9 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
以下に示す表は、上記の実施例についてまとめた表である。 The following table summarizes the above examples.
[比較例1]
精製水400mLに、パラオキシ安息香酸ブチル0.063gを添加し、加熱攪拌溶解した後、エリスリトール90g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 1]
After adding 0.063 g of butyl paraoxybenzoate to 400 mL of purified water and dissolving with heating and stirring, 90 g of erythritol, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0.6 g of sucralose, 0.75 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例2]
精製水400mLに、パラオキシ安息香酸ブチル0.126gを添加し、加熱攪拌溶解した後、エリスリトール90g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 2]
After adding 0.126 g of butyl paraoxybenzoate to 400 mL of purified water and dissolving with heating and stirring, 90 g of erythritol, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0.6 g of sucralose, 0.75 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例3]
精製水400mLに、パラオキシ安息香酸ブチル0.18gを添加し、加熱攪拌溶解した後、エリスリトール90g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを5.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 3]
To 400 mL of purified water, 0.18 g of butyl paraoxybenzoate was added and dissolved by stirring with heating. Then, 90 g of erythritol, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0.6 g of sucralose, 0.75 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 5.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例4]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを3.6に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 4]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, caramel 0.75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 3.6, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例5]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.3に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 5]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, caramel 0.75 g and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.3, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例6]
加温した精製水400mLに、エリスリトール90gを攪拌溶解し、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.6に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 6]
In 400 mL of heated purified water, 90 g of erythritol was stirred and dissolved. 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, and sucralose 6 g, 0.75 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.6, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例7]
加温した精製水400mLに、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 7]
To 400 mL of heated purified water, 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0.6 g of sucralose, 0.75 g of caramel, After adding the fragrance | flavor sequentially, stirring, after confirming melt | dissolution, after adjusting pH to 4.0, it is made up to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例8]
加温した精製水400mLに、D−ソルビトール90gを攪拌溶解し、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを3.5に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 8]
In 400 mL of heated purified water, 90 g of D-sorbitol was stirred and dissolved, and 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0.6 g of sucralose, 0. 75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 3.5, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例9]
加温した精製水400mLに、D−ソルビトール240gを攪拌溶解し、アマルティシロップ240g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 9]
In 400 mL of heated purified water, 240 g of D-sorbitol was dissolved with stirring, 240 g of amalty syrup, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, 1.5 g of diphenhydramine hydrochloride, 0. 75 g and a fragrance are sequentially added while stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例10]
精製水400mLに、パラオキシ安息香酸ブチル0.063gを添加し、加熱攪拌溶解した後、エリスリトール30g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.6g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.4に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 10]
After adding 0.063 g of butyl paraoxybenzoate to 400 mL of purified water and dissolving with heating and stirring, erythritol 30 g, sodium citrate 7.2 g, citric acid 3.45 g, malic acid 4.5 g, diphenhydramine hydrochloride 1.5 g, 0.6 g of sucralose, 0.75 g of caramel and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.4, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
[比較例11]
精製水400mLに、白糖300gを添加し、加熱攪拌溶解した後、アマルティシロップ30g、安息香酸ナトリウム0.63g、クエン酸ナトリウム7.2g、クエン酸3.45g、リンゴ酸4.5g、塩酸ジフェンヒドラミン1.5g、スクラロース0.15g、カラメル0.75g及び、香料を攪拌しながら順次添加し、溶解を確認した後、pHを4.0に調整後、精製水で全量900mLとする。濾紙を濾過層とした装置を使い本製剤を濾過した後、30mL褐色瓶に充填し、キャップを施し、85℃で15分滅菌した。
[Comparative Example 11]
After adding 300 g of white sugar to 400 mL of purified water and dissolving with heating and stirring, 30 g of amalty syrup, 0.63 g of sodium benzoate, 7.2 g of sodium citrate, 3.45 g of citric acid, 4.5 g of malic acid, diphenhydramine hydrochloride 1.5 g, sucralose 0.15 g, caramel 0.75 g and a fragrance are sequentially added with stirring, and after confirming dissolution, the pH is adjusted to 4.0, and the total volume is adjusted to 900 mL with purified water. The preparation was filtered using a filter paper filter device, filled in a 30 mL brown bottle, capped, and sterilized at 85 ° C. for 15 minutes.
以下に示す表は、上記の比較例をまとめた表である。 The table shown below is a table summarizing the above comparative examples.
[試験例1] 安定性試験(残存率)
実施例1〜8及び、比較例1〜10で得られた内服液剤を40℃の条件下、2、4及び6ヶ月保存した後、塩酸ジフェンヒドラミンの含量を測定した。なお、塩酸ジフェンヒドラミンは、逆相分配高速液体クロマトグラフィー法により定量を行った。。
測定後、以下の式により塩酸ジフェンヒドラミンの残存率を算出した。
残存率(%)=Ws/Wo×100
Ws: 40℃、2、4及び6ヵ月後の塩酸ジフェンヒドラミン含量
Wo: 製造直後の塩酸ジフェンヒドラミン含量
[Test Example 1] Stability test (residual rate)
The oral liquids obtained in Examples 1 to 8 and Comparative Examples 1 to 10 were stored at 40 ° C. for 2, 4 and 6 months, and then the content of diphenhydramine hydrochloride was measured. In addition, diphenhydramine hydrochloride was quantified by a reverse phase partition high performance liquid chromatography method. .
After the measurement, the residual ratio of diphenhydramine hydrochloride was calculated by the following formula.
Residual rate (%) = Ws / Wo × 100
Ws: Diphenhydramine hydrochloride content after 40 ° C, 2, 4 and 6 months Wo: Diphenhydramine hydrochloride content immediately after production
上記の安定性試験を行った結果を下記の表3に示した。
表3の結果から明らかなように、pH3.8より低いpH域の比較例4、比較例8では、塩酸ジフェンヒドラミンの経時安定性は悪くなり、含量低下が認められた。
The results of the above stability test are shown in Table 3 below.
As is apparent from the results in Table 3, in Comparative Examples 4 and 8 in the pH range lower than pH 3.8, the temporal stability of diphenhydramine hydrochloride was deteriorated and a decrease in the content was observed.
[試験例2] 保存効力試験
実施例1〜8及び、比較例1〜10の処方の内服液剤について、第十五改正日本薬局方 参考情報 「保存効力試験法」に準拠し、保存効力試験を実施した。本試験の場合、試験菌として、Escherichia coli(E.coli), Pseudomonas aeruginosa(P.aeru), Staphylococcus aureus(S.aureu) の細菌類及び Aspergillus niger(A.niger), Candida albicans(C.albi)の真菌類を用いて、接種生菌数と14日目の生菌数をカウントして減少率を計算した。
[Test Example 2] Preservative Efficacy Test Concerning the internal use liquids of the prescriptions of Examples 1 to 8 and Comparative Examples 1 to 10, the preservative efficacy test was conducted according to the Fifteenth Amendment Japanese Pharmacopoeia Reference Information Carried out. In the case of this test, bacteria of Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeru), Staphylococcus aureus (S. aureu) and Aspergillus niger (A. b. Al. The number of viable bacteria and the number of viable bacteria on the 14th day were counted and the reduction rate was calculated.
上記の保存効力試験を行った結果を下記の表4に示した。
表4の結果から明らかなように、pH4.2より高いpH域の比較例5、比較例6では、所定の菌に対する保存効力が低下した。
また、エリスルトールを配合しない比較例7では、効果がやや弱くなる。安息香酸ナトリウムまたは、パラベン類などの保存剤を配合しない比較例8、比較例9では、保存効力は認められなかった。
The results of the above preservation efficacy test are shown in Table 4 below.
As is clear from the results in Table 4, in Comparative Example 5 and Comparative Example 6 in a pH range higher than pH 4.2, the storage efficacy against a given bacterium was reduced.
Moreover, in the comparative example 7 which does not mix | blend erythritol, an effect becomes a little weak. In Comparative Example 8 and Comparative Example 9 in which no preservative such as sodium benzoate or parabens was blended, no preservative effect was observed.
[試験例3] 香味試験
評価パネル20名により、実施例1〜8及び、比較例1〜10の各組成物の「香味」、「甘味・酸味のバランス」についての評価を行った。「香味」、「甘味・酸味のバランス」の評価は、各検体を口に含んだ後、風味を確認した後、流しなどに吐き出すようにし、評価を行った。
[Test Example 3] Flavor Test Evaluations were made on the “flavor” and “sweetness / acidity balance” of each composition of Examples 1 to 8 and Comparative Examples 1 to 10 by 20 evaluation panels. Evaluation of “flavor” and “sweetness / acidity balance” was carried out after each sample was put in the mouth, after confirming the flavor, and then exhaling in a sink.
上記の香味試験を行った結果を下記の表5に示した。
表5の結果から明らかなように、実施例1〜8では、香味、甘味・酸味のバランスの両項目について、基準とする12名以上(60%以上)が良好と回答しているのに対し、ブチルパラベンを配合する比較例1〜3、エリスリトールあるいはスクラロースまたは、どちらも配合しない比較例7〜9また、ブチルパラベン配合し、エリスリトールの量が本発明より少ない比較例10においては、香味、甘味・酸味のバランスの評価は60%に満たなかった。
The results of the above flavor test are shown in Table 5 below.
As is clear from the results in Table 5, in Examples 1 to 8, 12 or more (60% or more) as the reference responded that both flavor and sweetness / acidity balance were good. Comparative Examples 1 to 3, butyl paraben blended, erythritol or sucralose, or Comparative Examples 7 to 9 blended with neither butyl paraben In Comparative Example 10 blended with butyl paraben and containing less erythritol than the present invention, flavor, sweetness -The evaluation of the balance of sourness was less than 60%.
上記の試験例1〜3をもとに、総合評価を行った。各試験例については、それぞれ以下に示す評価基準で評価を行った。 Comprehensive evaluation was performed based on the above Test Examples 1 to 3. Each test example was evaluated according to the following evaluation criteria.
[試験例1の評価基準]
○:40℃、6ヶ月保存後のジフェンヒドラミン残存率が、95%以上
△:40℃、6ヶ月保存後のジフェンヒドラミン残存率が、90%以上かつ95%未満
×:40℃、6ヶ月保存後のジフェンヒドラミン残存率が、90%未満
[Evaluation criteria of Test Example 1]
○: Diphenhydramine residual rate after storage at 40 ° C. for 6 months is 95% or more Δ: Diphenhydramine residual rate after storage at 40 ° C. for 6 months is 90% or more and less than 95% ×: After storage at 40 ° C. for 6 months Diphenhydramine residual rate is less than 90%
[試験例2の評価基準]
○:摂取した各細菌類に対する2週間培養後の菌数の割合が1%以下、
又は各真菌類に対する2週間培養後の菌数の割合が1%以下
△:摂取した各細菌類に対する2週間培養後の菌数の割合が10%以下、
又は各真菌類に対する2週間培養後の菌数の割合が摂取菌数のレベル以下
×:摂取した各細菌類に対する2週間培養後の菌数の割合が10%を超える、
又は各真菌類に対する2週間培養後の菌数の割合が摂取菌数のレベルを超える。
[Evaluation criteria of Test Example 2]
○: The ratio of the number of bacteria after 2 weeks of culture for each ingested bacteria is 1% or less,
Or the ratio of the number of bacteria after 2 weeks of culture for each fungus is 1% or less
Δ: The ratio of the number of bacteria after culturing for 2 weeks to each ingested bacteria is 10% or less,
Or the ratio of the number of bacteria after 2 weeks of culture for each fungus is below the level of the number of ingested bacteria
X: The ratio of the number of bacteria after 2 weeks of culture for each ingested bacteria exceeds 10%,
Or the ratio of the number of bacteria after 2 weeks culture | cultivation with respect to each fungus exceeds the level of the number of ingested bacteria.
[試験例3の評価基準]
◎:20名中、14名以上のパネルが、香味、甘味・酸味のバランスの両方の要因を
ともに良好と回答した。
○:20名中、12名以上のパネルが、良好であると評価した。
×:20名中、良好であると評価したパネルが、11名以下の場合。
[Evaluation criteria of Test Example 3]
A: More than 14 out of 20 panelists answered that both the flavor and sweetness / acidity balance factors were good.
○: Among 20 people, 12 or more panels were evaluated as good.
X: When the panel evaluated as favorable among 20 persons is 11 persons or less.
上記の総合評価の結果をまとめたものを、以下の表6に示す。各評価基準について全て適合したものは、総合評価○とした。また、一つでも評価基準が適合しないものは、本発明の医薬品として使用することはできないため、総合評価を×とした。 Table 6 below summarizes the results of the comprehensive evaluation described above. Those that met all of the evaluation criteria were evaluated as comprehensive evaluation ○. Moreover, since even one that does not meet the evaluation criteria cannot be used as the pharmaceutical product of the present invention, the overall evaluation is x.
[試験例4] 実施例2と比較例11の血糖値の測定評価
12時間絶食後のマウス(1群6匹)に実施例2の低カロリー液剤と白糖を使用した比較例11を1.5mL/kg相当を投与し、投与後120分までの血糖値の変化を30分ごとに測定した。実施例2の血糖値上昇は、比較例11投与群と比較して、極めて低いことが確認された。
Test Example 4 Measurement and Evaluation of Blood Glucose Levels of Example 2 and Comparative Example 11 1.5 mL of Comparative Example 11 using the low-calorie liquid of Example 2 and sucrose in mice after 12-hour fasting (6 mice per group) / Kg equivalent was administered, and changes in blood glucose level up to 120 minutes after administration were measured every 30 minutes. It was confirmed that the increase in blood glucose level in Example 2 was extremely low as compared with the administration group of Comparative Example 11.
上記の測定値を下記の表7に示す。
[図1]
The measured values are shown in Table 7 below.
[Figure 1]
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007327657A JP5211677B2 (en) | 2007-12-19 | 2007-12-19 | Oral solution |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007327657A JP5211677B2 (en) | 2007-12-19 | 2007-12-19 | Oral solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009149545A JP2009149545A (en) | 2009-07-09 |
JP5211677B2 true JP5211677B2 (en) | 2013-06-12 |
Family
ID=40919141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007327657A Active JP5211677B2 (en) | 2007-12-19 | 2007-12-19 | Oral solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5211677B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5347753B2 (en) | 2009-06-24 | 2013-11-20 | ソニー株式会社 | Power supply unit, processing system, and control method |
RU2016122224A (en) * | 2013-12-20 | 2017-12-11 | Дзе Проктер Энд Гэмбл Компани | Stable liquid drug containing diphenhydramine |
JP7062368B2 (en) * | 2017-03-15 | 2022-05-06 | 武田テバファーマ株式会社 | Oral pharmaceutical composition masked with unpleasant taste |
JP2023119520A (en) * | 2022-02-16 | 2023-08-28 | ヱスビー食品株式会社 | Antiallergic agent and food composition for allergy inhibition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
JPH0827034A (en) * | 1994-07-14 | 1996-01-30 | Nikken Chem Co Ltd | Liquid agent for internal use containing erythritol |
JP2003095933A (en) * | 2001-09-26 | 2003-04-03 | Lion Corp | Internal liquid agent composition |
-
2007
- 2007-12-19 JP JP2007327657A patent/JP5211677B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2009149545A (en) | 2009-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9089528B2 (en) | Liquid compositions of calcium acetate | |
ME01664B (en) | A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer | |
RU2668882C2 (en) | Liquid pharmaceutical composition | |
US11446246B2 (en) | Suspensions and diluents for metronidazole and baclofen | |
US11766441B2 (en) | Oral liquid compositions including chlorpromazine | |
JP5211677B2 (en) | Oral solution | |
JP2009256216A (en) | Liquid amlodipine besylate formulation for internal administration stable in solution state | |
US11219610B2 (en) | Bolus dose of hydroxycitric acid with glycerol | |
JP6410814B2 (en) | Liquid pharmaceutical composition for oral administration containing fexofenadine | |
UA129270C2 (en) | Pediatric trazodone compositions and method of treatment thereof | |
JP2008094743A (en) | Food for improving eating and swallowing | |
JP2007269786A (en) | Pantethine-containing oral liquid preparation | |
KR20120031051A (en) | Oral liquid preparation | |
JP6856813B1 (en) | Zinc Intravenous Infusion Formulation | |
WO2011095801A2 (en) | Pharmaceutical composition | |
JP5823131B2 (en) | A composition containing windproof tsushosan | |
EP1894557B1 (en) | Liquid composition for prevention and/or treatment of different bone metabolic diseases, uses thereof, and preparation process therefore | |
JP4195218B2 (en) | Pharmaceutical solution containing a drug stabilized by weak alkali | |
Dawson et al. | Guidelines for compounding oral medications for pediatric patients | |
JP2007291011A (en) | Preventive or therapeutic agent for inflammatory bowel disease | |
JP2009001592A (en) | Medicinal liquid agent including medicine stabilized with weak alkali | |
TW200800152A (en) | Antifatigue composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101007 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121225 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20121225 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130129 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130211 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5211677 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160308 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |